Results
eNauka >
Rezultati >
Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
| Naziv: | Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC | Autori  : | Cho, BC; ...; Secen, Nevena M; ...; (broj, koautora 19) | Godina: | 2021 | Publikacija: | ANNALS OF ONCOLOGY | ISSN: | 0923-7534 Annals of Oncology Pretraži identifikator |
Tip rezultata: | Konferencijski rad | Kolacija: | vol. 32 str. S1428-S1428 | DOI: | 10.1016/j.annonc.2021.10.217 | WoS-ID: | 000731051400120 | URI: | https://enauka.gov.rs/handle/123456789/823623 | Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | Mp kategorija će biti prikazana naknadno. |
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.